All In Biotech

Drug Trial Radar · NCT06393452

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Jun 5, 2024

Primary completion

Jul 16, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
Pelage Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.

Conditions

  • Androgenetic Alopecia

Interventions

  • PP405 0.05% Topical GelDrug

    Medicated topical gel containing PP405 0.05%, applied once daily to the scalp

  • Topical Vehicle GelDrug

    Vehicle = placebo topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Adverse EventsTime frame: Baseline to Day 84 of the randomized portion of the study
  2. Percentage of Subjects With Adverse EventsTime frame: Baseline to Day 84 of the open label extension portion of the study
  3. Change in Local Dermal Tolerability as Assessed by Subject and InvestigatorTime frame: Post-dose at day 28 of the randomized portion of the study
  4. Change in Local Dermal Tolerability as Assessed by Subject and InvestigatorTime frame: Post-dose at day 84 of the open label extension portion of the study
  5. Change From Baseline in Blood PressureTime frame: Baseline to Day 84 of the randomized portion of the study
  6. Change From Baseline in Pulse RateTime frame: Baseline to Day 84 of the randomized portion of the study
  7. Change From Baseline in TemperatureTime frame: Baseline to Day 84 of the randomized portion of the study
  8. Change From Baseline in Respiratory RateTime frame: Baseline to Day 84 of the randomized portion of the study
  9. Change From Baseline in WeightTime frame: Baseline to Day 84 of the randomized portion of the study
  10. Change From Baseline in Blood PressureTime frame: Baseline to Day 84 of the open label extension portion of the study
  11. Change From Baseline in Pulse RateTime frame: Baseline to Day 84 of the open label extension portion of the study
  12. Change From Baseline in TemperatureTime frame: Baseline to Day 84 of the open label extension portion of the study
  13. Change From Baseline in Respiratory RateTime frame: Baseline to Day 84 of the open label extension portion of the study
  14. Change From Baseline in WeightTime frame: Baseline to Day 84 of the open label extension portion of the study
  15. Change From Baseline in Mean Electrocardiogram Heart RateTime frame: Baseline to day 28 of the randomized portion of the study
  16. Change From Baseline in Electrocardiogram (ECG) ResultsTime frame: Baseline to day 28 of the randomized portion of the study
  17. Change From Baseline in Mean Electrocardiogram Heart RateTime frame: Baseline to day 84 of the open label extension portion of the study
  18. Change From Baseline in Electrocardiograms (ECGs)Time frame: Baseline to day 84 of the open label extension portion of the study
  19. Abnormal Laboratory ValuesTime frame: Day 28 post baseline in the randomized portion of the study
  20. Abnormal Laboratory ValuesTime frame: Day 84 post baseline in the open label extension portion of the study

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Clinical Trials Research Institute

    Thousand Oaks, California

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • DermResearch

    Austin, Texas

  • Stride Clinical Research LLC

    Sugar Land, Texas

  • Jordan Valley Dermatology Center

    South Jordan, Utah

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.